We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]
Fewer visual side effects reported with Vivity IOL
Rowen S, et al. Clinical results of a new extended range of vision IOL. Presented at: Hawaiian Eye; May 8-14, 2021; Wailea, Hawaii.
Rowen reports she is a consultant and speaker for Alcon, Allergan, Bausch + Lomb, Ivantis, Kala and Tarsus.
WAILEA, Hawaii — The AcrySof IQ Vivity IOL features less glare and fewer halos with “significantly fewer complaints” than previously studied multifocal IOLs, according to a speaker at Hawaiian Eye 2021.
“The Vivity extended vision IOL (Alcon) offers the same range of vision with contrast sensitivity similar to a monofocal lens, and the design suggests decreased incidence of unwanted visual side effects,” Sheri L. Rowen, MD, FACS, said.
Rowen and colleagues conducted a retrospective analysis of clinical outcomes and patient satisfaction. Patients sought an extended range of vision with a decreased risk for halos and were willing to continue wearing reading glasses, Rowen said. Additionally, patients could not be candidates for diffractive multifocal technology, had no highly significant visually debilitating issues and had to be willing to mix a Vivity IOL with a PanOptix IOL (Alcon).
Sheri L. Rowen
Clinical outcomes included visual acuity at all distances, and study participants filled out a patient satisfaction survey.
At 1 month, 76% of patients had uncorrected monocular distance visual acuity of 20/25 or better, while 82% of patients had 20/20 or better uncorrected intermediate visual acuity. For uncorrected near visual acuity, 88% of patients had vision of J3 or greater, Rowen said.
No patients who received only the Vivity IOL experienced glare symptoms, and 3% of patients who received mix-and-match IOLs reported glare. Eleven percent of patients who received only the Vivity IOL reported mild halos, with 89% reporting no symptoms; 21% of patients who received mix-and-match IOLs reported moderate halos, 14% reported mild halos and 65% reported no symptoms. Sixty-five percent of patients reported independence from glasses, with 35% using glasses for fine print only. Patients who received a Vivity IOL or mix-and-match lenses rated their happiness with the Vivity highly, with 85% scoring nine or 10 out of 10.
“In conclusion, the Vivity has been a great addition to our refractive cataract practice. It’s certainly delivered on less glare and halos, and we are having a better than expected spectacle independence and unwanted visual side effects,” Rowen said.